Last reviewed · How we verify
Sirion Therapeutics, Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Difluprednate Ophthalmic Emulsion | Difluprednate Ophthalmic Emulsion | marketed |
Therapeutic area mix
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Sirion Therapeutics, Inc.:
- Sirion Therapeutics, Inc. pipeline updates — RSS
- Sirion Therapeutics, Inc. pipeline updates — Atom
- Sirion Therapeutics, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sirion Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sirion-therapeutics-inc. Accessed 2026-05-16.